The content on this site is intended for healthcare professionals only
Dr Thomas Powles from Barts Cancer Institute, London, UK, talks to ecancer with several leading renal oncologists at ECC 2013 held in Amsterdam between 27 September to 1 October 2013.
Focusing on highlights from the congress, the experts share their views of the latest real-world data with pazopanib. Dr. Matrana gives an overview of the 2-year results from MD Anderson presented at the meeting and Dr. Galvis outlines the real-world Christie Manchester, UK, experience with pazopanib. Both confirmed that pazopanib was as effective and well-tolerated as it has been in the clinical trial setting, and they discuss their results. Observed toxicity in the real-world setting is also discussed, including how to manage hypertension and transaminitis in clinical practice, and the possibility of drug interactions.
Finally, the panel comment on the use of pazopanib in the first-line setting.
This programme has been supported by a grant from GlaxoSmithKline.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
